v3.25.1
Balance Sheet Details - Schedule of Intangible Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Intangible Assets [Line Items]    
Balance Beginning $ 25,410,887
Additions   39,356,771
Measurement period adjustments related to the Proteomedix acquisition (Note 5) (10,321,000)  
Impairment (13,576,440) (14,610,128)
Amortization (709,042) (36,812)
Effect of Foreign Currency Translation (804,405) 701,056
Balance Ending 25,410,887
Trade Names [Member]    
Schedule of Intangible Assets [Line Items]    
Balance Beginning 9,312,739
Additions   9,018,000
Measurement period adjustments related to the Proteomedix acquisition (Note 5) (6,239,000)  
Impairment (2,676,441)
Amortization (185,396)
Effect of Foreign Currency Translation (211,902) 294,739
Balance Ending 9,312,739
Product rights for developed technology [Member]    
Schedule of Intangible Assets [Line Items]    
Balance Beginning 14,150,944
Additions   28,447,771
Measurement period adjustments related to the Proteomedix acquisition (Note 5) (3,264,000)  
Impairment (9,912,392) (14,610,128)
Amortization (457,144) (31,213)
Effect of Foreign Currency Translation (517,408) 344,514
Balance Ending 14,150,944
Customer Relationships [Member]    
Schedule of Intangible Assets [Line Items]    
Balance Beginning 1,947,204
Additions   1,891,000
Measurement period adjustments related to the Proteomedix acquisition (Note 5) (818,000)  
Impairment (987,607)
Amortization (66,502) (5,599)
Effect of Foreign Currency Translation (75,095) 61,803
Balance Ending $ 1,947,204